The FDAAA effect
Executive Summary
The FDA Amendments Act will cause a fundamental shift toward a greater emphasis on drug safety within FDA, Covington & Burling Partner Richard Kingham suggests. "Inevitably, many provisions of the law, even the transfer of more of the PDUFA registration fee money to the drug safety side of the agency, are going to change the equilibrium in terms of where the emphasis is in the review process and postmarket labeling regulatory control process," he says at the Drug Information Association's pharmacovigilance meeting Jan. 14...
You may also be interested in...
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.